Statements (52)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:bfsLayer |
3
|
gptkbp:bfsParent |
gptkb:Research_Institute
|
gptkbp:advocates_for |
gptkb:hospital
gptkb:physicist Policy makers |
gptkbp:aims_to |
Patient outcomes
|
gptkbp:applies_to |
gptkb:Cardiovascular_diseases
Cancer treatment Rare diseases |
gptkbp:collaborated_with |
gptkb:physicist
Healthcare providers Technology companies |
gptkbp:defines |
An innovative approach to tailoring disease treatment and prevention strategies to individual characteristics.
|
gptkbp:focuses_on |
Environmental factors
Lifestyle choices Genetic information |
https://www.w3.org/2000/01/rdf-schema#label |
Precision Medicine
|
gptkbp:involves |
Personalized therapies
Targeted drug development |
gptkbp:is_adopted_by |
Pharmaceutical industry
Healthcare systems Insurance providers |
gptkbp:is_challenged_by |
Ethical concerns
Access to technology Data privacy issues Regulatory hurdles Public understanding Clinical implementation barriers |
gptkbp:is_evaluated_by |
Cost-effectiveness
Patient satisfaction Clinical outcomes |
gptkbp:is_explored_in |
Genetic testing
Biomarker discovery Disease prevention strategies |
gptkbp:is_influenced_by |
Lifestyle factors
Family history Patient genetics |
gptkbp:is_promoted_by |
gptkb:National_Institutes_of_Health_(NIH)
Research institutions Pharmaceutical companies |
gptkbp:is_related_to |
gptkb:Company
Clinical trials Pharmacogenomics |
gptkbp:is_supported_by |
gptkb:Artificial_Intelligence
gptkb:Government_initiatives Data analytics Public health organizations Patient advocacy groups Advances in genomics |
gptkbp:utilizes |
Biomarkers
Genomic data |